Progression-Free Survival by Prior Somatostatin Analog Use and Primary Tumor Site and Updated Safety Results in Patients with Advanced Neuroendocrine Tumors and a History of Carcinoid Syndrome: A RADIANT-2 Analysis

#496

Introduction: In RADIANT-2, patients (pts) with advanced neuroendocrine tumors (NET) on Everolimus (E, 10 mg/d) + octreotide LAR (O, 30 mg q28d) had clinically meaningful improvement in progression-free survival (PFS) v. placebo (P)+O (16.4 mo v. 11.3 mo, respectively).

Aim(s): To report the effect of prior somatostatin analog (SSA) therapy and primary tumor site on PFS and updated safety.

Materials and methods: Pts were randomly assigned to E+O (n=216) or P+O (n=213); 80% and 78% had prior SSA therapy at enrollment, respectively; >90% were on O.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Pavel M, Singh N, Passos V, Strosberg J,

Keywords: Everolimus, Octreotide, mTOR,